Biomodal

biomodal develops a duet multiomics platform that generates genetic and epigenetic data from a single DNA sample in a single experiment, providing researchers with access to the 6-base genome. The company duet multiomics solution evoC distinguishes all four canonical DNA bases plus 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) from as little as 5ng of DNA, enabling combined epigenetic and genetic analysis in a single sequencing run. This technology overcomes the limitations of current approaches that cannot reliably resolve both genetic and epigenetic sequences at low sample input, missing critical biological information. The duet evoC platform is particularly valuable for liquid biopsy applications, where it simultaneously profiles 5mC, 5hmC, genetic variants, and fragmentomics features from a single cfDNA sample, achieving ultra-low limits of detection through single-stranded ligation that enhances material recovery with outstanding sensitivity and specificity. biomodal also offers the duet multiomics solution +modC for assessing all four canonical bases plus modified cytosine, custom solutions, and the modality XPLR analysis tool with modality Viewer. The platform serves research applications including cancer research for better characterizing liquid biopsy and genomic DNA samples of early-stage cancer, neurodegenerative disease research revealing the role of methylation in neurodegeneration, ageing research pinpointing epigenetic changes that determine disease and health patterns, precision medicine for improved DNA-based diagnostics, and non-invasive prenatal testing. Published research demonstrates dual 5mC/5hmC profiling in metastatic prostate cancer enabling transcriptome-like tumor-state and resistance monitoring. Founded in 2012 and headquartered in Cambridge, United Kingdom, biomodal has raised approximately $164.1 million in Series D funding from investors including Google Ventures, Sequoia Capital, Syncona, Temasek, Third Point, New Science Ventures, University of Cambridge, Ahren, and DNA Capital. The company employs approximately 97 people.

Genomics > Enabling Technologies > Technology Platforms > Epigenetics